ArticleMaterials today. Bio2025

A microfluidic tumor-on-chip platform deciphers hypoxia-driven FOXO3a/PD-L1 signaling in gastric cancer immunotherapy resistance.

Hanting Xiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.